Nrx pharmaceuticals (nasdaq:nrxp) completes memorandum of understanding and collaborations with distribution partners for htx-100 (iv ketamine)

Company to receive first allocation of ketamine for sale by month end partners preparing to ship iv ketamine to full range of customers via 503a and 503b pharmacies nrx pharmaceuticals and hope therapeutics aim to provide highest quality product available to those in need and assure ongoing supply important step toward goal of providing full suite of supply options, to ultimately include an fda approved, and widely reimbursed, solution for patients and clinics, subject to board approval radnor, pa. , march 11, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company") and its wholly owned subsidiary hope therapeutics, clinical-stage biopharmaceutical companies, today announced completion of a memorandum of understanding with conversio health, a national 503a pharmacy, and a strong, ongoing partnership with nephron pharmaceuticals, a manufacturer of ketamine and 503b pharmacy to provide iv ketamine to patients and clinics across the country, subject to board approval.
NRXP Ratings Summary
NRXP Quant Ranking